Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleOMERACT 11

Updating the OMERACT Filter: Implications for Patient-reported Outcomes

John R. Kirwan, Susan J. Bartlett, Dorcas E. Beaton, Maarten Boers, Ailsa Bosworth, Peter M. Brooks, Ernest Choy, Maarten de Wit, Francis Guillemin, Sarah Hewlett, Tore K. Kvien, Robert B. Landewé, Amye L. Leong, Anne Lyddiatt, Lyn March, James May, Pamela Lesley Montie, Enkeleida Nikaï, Pam Richards, Marieke M.J.H. Voshaar, Wilma Smeets, Vibeke Strand, Peter Tugwell and Laure Gossec
The Journal of Rheumatology May 2014, 41 (5) 1011-1015; DOI: https://doi.org/10.3899/jrheum.131312
John R. Kirwan
From the University of Bristol, Academic Rheumatology Unit, and the University of the West of England, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Department of Occupational Sciences and Occupational Therapy, Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Departments of Epidemiology and Biostatistics, and Rheumatology, and Department of Medical Humanities, VU University Medical Center, Amsterdam, The Netherlands; National Rheumatoid Arthritis Society, Maidenhead, Berkshire, UK; Faculty of Health Sciences, University of Queensland, Royal Brisbane and Women’s Hospital, Herston, Brisbane, Australia; Section of Rheumatology, Cardiff University School of Medicine, Cardiff, UK; Université de Lorraine, Université Paris Descartes, Paris, France; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center Heerlen, Amsterdam, The Netherlands; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Cochrane Musculoskeletal Group, Institute of Population Health, Ottawa, Ontario, Canada; Department of Rheumatology, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Consumer Advisory Board, Arthritis Research Centre of Canada, Richmond, British Columbia, Canada; UCB Pharma S.A., Brussels, Belgium; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Université Pierre et Marie Curie (UPMC) — Paris 6, GRC-UMPC 08 (EEMOIS); AP-HP Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: john.kirwan@bristol.ac.uk
Susan J. Bartlett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorcas E. Beaton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maarten Boers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ailsa Bosworth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter M. Brooks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ernest Choy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maarten de Wit
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francis Guillemin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Hewlett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tore K. Kvien
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert B. Landewé
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amye L. Leong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Lyddiatt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lyn March
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James May
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela Lesley Montie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enkeleida Nikaï
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pam Richards
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marieke M.J.H. Voshaar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wilma Smeets
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vibeke Strand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Tugwell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laure Gossec
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. At a previous Outcome Measures in Rheumatology (OMERACT) meeting, participants reflected on the underlying methods of patient-reported outcome (PRO) instrument development. The participants requested proposals for more explicit instrument development protocols that would contribute to an enhanced version of the “Truth” statement in the OMERACT Filter, a widely used guide for outcome validation. In the present OMERACT session, we explored to what extent these new Filter 2.0 proposals were practicable, feasible, and already being applied.

Methods. Following overview presentations, discussion groups critically reviewed the extent to which case studies of current OMERACT Working Groups complied with or negated the proposed PRO development framework, whether these observations had a more general application, and what issues remained to be resolved.

Results. Several aspects of PRO development were recognized as particularly important, and the need to directly involve patients at every stage of an iterative PRO development program was endorsed. This included recognition that patients contribute as partners in the research and not merely as subjects. Correct communication of concepts with the words used in questionnaires was central to their performance as measuring instruments, and ensuring this understanding crossed cultural and linguistic boundaries was important in international studies or comparisons.

Conclusion. Participants recognized, endorsed, and were generally already putting into practice the principles of PRO development presented in the plenary session. Further work is needed on some existing instruments and on establishing widespread good practice for working in close collaboration with patients.

Key Indexing Terms:
  • OUTCOME AND PROCESS ASSESSMENT
  • PATIENT-REPORTED OUTCOMES
  • RANDOMIZED CONTROLLED TRIALS
View Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 5
1 May 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Updating the OMERACT Filter: Implications for Patient-reported Outcomes
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Updating the OMERACT Filter: Implications for Patient-reported Outcomes
John R. Kirwan, Susan J. Bartlett, Dorcas E. Beaton, Maarten Boers, Ailsa Bosworth, Peter M. Brooks, Ernest Choy, Maarten de Wit, Francis Guillemin, Sarah Hewlett, Tore K. Kvien, Robert B. Landewé, Amye L. Leong, Anne Lyddiatt, Lyn March, James May, Pamela Lesley Montie, Enkeleida Nikaï, Pam Richards, Marieke M.J.H. Voshaar, Wilma Smeets, Vibeke Strand, Peter Tugwell, Laure Gossec
The Journal of Rheumatology May 2014, 41 (5) 1011-1015; DOI: 10.3899/jrheum.131312

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Updating the OMERACT Filter: Implications for Patient-reported Outcomes
John R. Kirwan, Susan J. Bartlett, Dorcas E. Beaton, Maarten Boers, Ailsa Bosworth, Peter M. Brooks, Ernest Choy, Maarten de Wit, Francis Guillemin, Sarah Hewlett, Tore K. Kvien, Robert B. Landewé, Amye L. Leong, Anne Lyddiatt, Lyn March, James May, Pamela Lesley Montie, Enkeleida Nikaï, Pam Richards, Marieke M.J.H. Voshaar, Wilma Smeets, Vibeke Strand, Peter Tugwell, Laure Gossec
The Journal of Rheumatology May 2014, 41 (5) 1011-1015; DOI: 10.3899/jrheum.131312
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • Presentations
    • Case Studies and Discussion Groups
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

OUTCOME AND PROCESS ASSESSMENT
PATIENT-REPORTED OUTCOMES
RANDOMIZED CONTROLLED TRIALS

Related Articles

Cited By...

More in this TOC Section

OMERACT 11

  • Updating the OMERACT Filter at OMERACT 11
  • Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets
  • How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0
Show more OMERACT 11

The OMERACT Filter 2.0

  • How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0
  • Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of “Truth”: Content, Face, and Construct Validity
  • Toward a Generalized Framework of Core Measurement Areas in Clinical Trials: A Position Paper for OMERACT 11
Show more The OMERACT Filter 2.0

Similar Articles

Keywords

  • outcome and process assessment
  • patient-reported outcomes
  • RANDOMIZED CONTROLLED TRIALS

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire